EHA Congress Virtual Meeting 2020 Conference Review

In this review:

Venetoclax with azacitidine vs azacitidine in AML
Mitapivat in non-transfusiondependent thalassemia
Pembrolizumab vs brentuximab vedotin for R/R Hodgkin lymphoma
Ruxolitinib vs best available therapy in steroid-refractory GvHD
Isatuximab plus Kd vs Kd in RRMM
Endotheliopathy is essential in COVID-19 associated coagulopathy
Imetelstat in low risk transfusion dependent MDS R/R to ESA
PET guided omission of RT in early-stage unfavourable Hodgkin lymphoma
Pegcetacoplan vs eculizumab in PNH
Zanubrutinib vs ibrutinib in Waldenström macroglobulinemia

Please login below to download this issue (PDF)